Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With Post-thrombotic Syndrome a Multi-center, International, Randomized, Open Label, Controlled Trial

NCT04128956 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT04128956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04128956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With Post-thrombotic Syndrome a Multi-center, International, Randomized, Open Label, Controlled Trial
Lead sponsor
University of Zurich
Phase
Phase 2
Overall status
Terminated
Start date
March 11, 2020
Completion date
February 21, 2024
Enrollment
172 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

stent stenosis, venous thromboses